Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut

This study explored a treatment combination (obinutuzumab, ibrutinib, and venetoclax) for a specific type of leukemia (chronic lymphocytic leukemia with del(17p) and/or TP53 mutation) in previously untreated patients. The treatment involved several cycles and aimed to achieve complete remission.

The results showed that 58.5% of patients achieved complete remission, and after around 3 years, the progression-free survival rate was 79.9%, with an overall survival rate of 92.6%. Some patients experienced side effects like neutropenia, infections, and cardiovascular issues, but these generally decreased over time.

In summary, this treatment regimen appears promising for high-risk chronic lymphocytic leukemia patients with manageable side effects.

Similar Posts